FCCC LOGO Faculty Publications
Schaeffer E , Srinivas S , Antonarakis ES , Armstrong AJ , Bekelman JE , Cheng H , D'Amico AV , Davis BJ , Desai N , Dorff T , Eastham JA , Farrington TA , Gao X , Horwitz EM , Ippolito JE , Kuettel MR , Lang JM , McKay R , McKenney J , Netto G , Penson DF , Pow-Sang JM , Reiter R , Richey S , Roach Iii M , Rosenfeld S , Shabsigh A , Spratt DE , Teply BA , Tward J , Shead DA , Freedman-Cass DA
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021
J Natl Compr Canc Netw. 2021 Feb 2;19(2) :134-143
Back to previous list
Abstract
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.
Notes
1540-1413 Schaeffer, Edward Srinivas, Sandy Antonarakis, Emmanuel S Armstrong, Andrew J Bekelman, Justin E Cheng, Heather D'Amico, Anthony Victor Davis, Brian J Desai, Neil Dorff, Tanya Eastham, James A Farrington, Thomas A Gao, Xin Horwitz, Eric Mark Ippolito, Joseph E Kuettel, Michael R Lang, Joshua M McKay, Rana McKenney, Jesse Netto, George Penson, David F Pow-Sang, Julio M Reiter, Robert Richey, Sylvia Roach Iii, Mack Rosenfeld, Stan Shabsigh, Ahmad Spratt, Daniel E Teply, Benjamin A Tward, Jonathan Shead, Dorothy A Freedman-Cass, Deborah A Journal Article United States J Natl Compr Canc Netw. 2021 Feb 2;19(2):134-143. doi: 10.6004/jnccn.2021.0008.